Combination Immunotherapy for Tumor Stem Cell Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively targeting and eradicating tumor stem cells and inducing long-lasting anti-tumor immune responses due to immune evasion mechanisms and inefficient T-cell induction and expansion.
Innovation Solution
A combination immunotherapy approach involving tumor sensitization through apoptosis-inducing treatments, in situ vaccination using modified stem cells with cytotoxic payloads, and T-cell activation using growth factors and checkpoint inhibitors to convert the tumor microenvironment into an immunogenic environment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat tumors, then tumor cells are killed, but tumor stem cells remain resistant and cause recurrence
Solution Approach 1:
The patent segments the tumor population by specifically identifying and targeting tumor stem cells (CSCs) as a distinct subset from bulk tumor cells. The combination therapy approach separates the treatment of differentiated tumor cells (using conventional therapies) from the targeting of resistant CSCs (using immunotherapy and stem cell-based approaches), thereby overcoming the resistance problem.
Solution Approach 2:
The patent employs a composite treatment approach by combining multiple therapeutic modalities: conventional chemotherapy/radiation, immunotherapy (checkpoint inhibitors, cytokines), and genetically modified stem cells with cytotoxic payloads. This composite strategy addresses both bulk tumor cells and resistant stem cells simultaneously, eliminating the limitation of single-modality treatments.
2Reliability
If immunotherapy is used to induce anti-tumor immune responses, then immune activation occurs, but immune evasion mechanisms prevent effective T-cell response
Solution Approach 1:
The patent applies preliminary anti-action by using checkpoint inhibitors and immunomodulatory agents to block immune evasion mechanisms before administering the main immunotherapy. The modified stem cells are also pre-equipped with cytotoxic payloads to counteract potential immune suppression, ensuring that the immune system can effectively recognize and attack tumor cells without being evaded.
Solution Approach 2:
The patent introduces intermediaries in the form of genetically modified stem cells that serve as carriers delivering cytotoxic payloads directly to tumor sites. These modified stem cells act as mediators between the immune system and tumor cells, facilitating effective immune response while bypassing immune evasion mechanisms through targeted delivery.
3Ease of operation
If single-modality therapy is used to treat cancer, then treatment simplicity is maintained, but treatment effectiveness against diverse tumor cells is insufficient
Solution Approach 1:
The patent merges multiple treatment modalities into a unified combination therapy protocol. Conventional therapies (chemotherapy, radiation) are combined with immunotherapy (checkpoint inhibitors, cytokines) and stem cell-based therapies (modified stem cells with cytotoxic payloads). This integration maintains operational simplicity through coordinated administration while achieving comprehensive tumor eradication by targeting both bulk tumor cells and resistant stem cells through different mechanisms.
Data Source
AI summary
Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response.